List of Tables
    Table 1. Diabetic Neuropathic Pain Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Diabetic Neuropathic Pain Drug Market Trends
    Table 3. Diabetic Neuropathic Pain Drug Market Drivers
    Table 4. Diabetic Neuropathic Pain Drug Market Challenges
    Table 5. Diabetic Neuropathic Pain Drug Market Restraints
    Table 6. Global Diabetic Neuropathic Pain Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Diabetic Neuropathic Pain Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Diabetic Neuropathic Pain Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Diabetic Neuropathic Pain Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Diabetic Neuropathic Pain Drug Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Diabetic Neuropathic Pain Drug Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Diabetic Neuropathic Pain Drug Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Diabetic Neuropathic Pain Drug Sales by Manufacturer, (K Pcs), 2017-2022
    Table 14. Global Diabetic Neuropathic Pain Drug Sales Share by Manufacturer, 2017-2022
    Table 15. Global Diabetic Neuropathic Pain Drug Price by Manufacturer (2017-2022) & (USD/Pcs)
    Table 16. Global Diabetic Neuropathic Pain Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2021)
    Table 18. Top Players of Diabetic Neuropathic Pain Drug in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Diabetic Neuropathic Pain Drug Product Type
    Table 20. Date of International Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Diabetic Neuropathic Pain Drug Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Diabetic Neuropathic Pain Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Diabetic Neuropathic Pain Drug Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Diabetic Neuropathic Pain Drug Sales by Players, (K Pcs), 2020, 2021 & 2022
    Table 26. United States Diabetic Neuropathic Pain Drug Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Diabetic Neuropathic Pain Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Diabetic Neuropathic Pain Drug Sales in Volume by Region (2017-2022) & (K Pcs)
    Table 29. Global Diabetic Neuropathic Pain Drug Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
    Table 30. Global Diabetic Neuropathic Pain Drug Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Diabetic Neuropathic Pain Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 33. North America Diabetic Neuropathic Pain Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Diabetic Neuropathic Pain Drug Sales in Volume by Region (2017-2028) & (K Pcs)
    Table 35. Asia Pacific Diabetic Neuropathic Pain Drug Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Diabetic Neuropathic Pain Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 37. Europe Diabetic Neuropathic Pain Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Diabetic Neuropathic Pain Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 39. Latin Americaa Diabetic Neuropathic Pain Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Volume by Country (2017-2028) & (K Pcs)
    Table 41. Middle East and Africa Diabetic Neuropathic Pain Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Astellas Pharma Inc. Corporation Information
    Table 43. Astellas Pharma Inc. Description and Business Overview
    Table 44. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 45. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product
    Table 46. Astellas Pharma Inc. Recent Development
    Table 47. AstraZeneca Plc Corporation Information
    Table 48. AstraZeneca Plc Description and Business Overview
    Table 49. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 50. AstraZeneca Plc Product
    Table 51. AstraZeneca Plc Recent Development
    Table 52. BioDelivery Sciences International, Inc. Corporation Information
    Table 53. BioDelivery Sciences International, Inc. Description and Business Overview
    Table 54. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 55. BioDelivery Sciences International, Inc. Product
    Table 56. BioDelivery Sciences International, Inc. Recent Development
    Table 57. Boehringer Ingelheim GmbH Corporation Information
    Table 58. Boehringer Ingelheim GmbH Description and Business Overview
    Table 59. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 60. Boehringer Ingelheim GmbH Product
    Table 61. Boehringer Ingelheim GmbH Recent Development
    Table 62. Daiichi Sankyo Company, Limited Corporation Information
    Table 63. Daiichi Sankyo Company, Limited Description and Business Overview
    Table 64. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 65. Daiichi Sankyo Company, Limited Product
    Table 66. Daiichi Sankyo Company, Limited Recent Development
    Table 67. Dong-A Socio Group Corporation Information
    Table 68. Dong-A Socio Group Description and Business Overview
    Table 69. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 70. Dong-A Socio Group Product
    Table 71. Dong-A Socio Group Recent Development
    Table 72. Eli Lilly and Company Corporation Information
    Table 73. Eli Lilly and Company Description and Business Overview
    Table 74. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 75. Eli Lilly and Company Product
    Table 76. Eli Lilly and Company Recent Development
    Table 77. Glenmark Pharmaceuticals Ltd. Corporation Information
    Table 78. Glenmark Pharmaceuticals Ltd. Description and Business Overview
    Table 79. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 80. Glenmark Pharmaceuticals Ltd. Product
    Table 81. Glenmark Pharmaceuticals Ltd. Recent Development
    Table 82. Hydra Biosciences, Inc. Corporation Information
    Table 83. Hydra Biosciences, Inc. Description and Business Overview
    Table 84. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 85. Hydra Biosciences, Inc. Product
    Table 86. Hydra Biosciences, Inc. Recent Development
    Table 87. Immune Pharmaceuticals Inc. Corporation Information
    Table 88. Immune Pharmaceuticals Inc. Description and Business Overview
    Table 89. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 90. Immune Pharmaceuticals Inc. Product
    Table 91. Immune Pharmaceuticals Inc. Recent Development
    Table 92. Laboratorios Del Dr. Esteve S.A. Corporation Information
    Table 93. Laboratorios Del Dr. Esteve S.A. Description and Business Overview
    Table 94. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 95. Laboratorios Del Dr. Esteve S.A. Product
    Table 96. Laboratorios Del Dr. Esteve S.A. Recent Development
    Table 97. Lohocla Research Corporation Corporation Information
    Table 98. Lohocla Research Corporation Description and Business Overview
    Table 99. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 100. Lohocla Research Corporation Product
    Table 101. Lohocla Research Corporation Recent Development
    Table 102. Mertiva AB Corporation Information
    Table 103. Mertiva AB Description and Business Overview
    Table 104. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 105. Mertiva AB Product
    Table 106. Mertiva AB Recent Development
    Table 107. Novaremed Corporation Information
    Table 108. Novaremed Description and Business Overview
    Table 109. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. Novaremed Product
    Table 111. Novaremed Recent Development
    Table 112. Pharmaleads Corporation Information
    Table 113. Pharmaleads Description and Business Overview
    Table 114. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. Pharmaleads Product
    Table 116. Pharmaleads Recent Development
    Table 117. RAPID Pharmaceuticals AG Corporation Information
    Table 118. RAPID Pharmaceuticals AG Description and Business Overview
    Table 119. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. RAPID Pharmaceuticals AG Product
    Table 121. RAPID Pharmaceuticals AG Recent Development
    Table 122. Relmada Therapeutics, Inc. Corporation Information
    Table 123. Relmada Therapeutics, Inc. Description and Business Overview
    Table 124. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 125. Relmada Therapeutics, Inc. Product
    Table 126. Relmada Therapeutics, Inc. Recent Development
    Table 127. Sphaera Pharma Pvt. Ltd. Corporation Information
    Table 128. Sphaera Pharma Pvt. Ltd. Description and Business Overview
    Table 129. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 130. Sphaera Pharma Pvt. Ltd. Product
    Table 131. Sphaera Pharma Pvt. Ltd. Recent Development
    Table 132. Theravasc, Inc. Corporation Information
    Table 133. Theravasc, Inc. Description and Business Overview
    Table 134. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 135. Theravasc, Inc. Product
    Table 136. Theravasc, Inc. Recent Development
    Table 137. Key Raw Materials Lists
    Table 138. Raw Materials Key Suppliers Lists
    Table 139. Diabetic Neuropathic Pain Drug Customers List
    Table 140. Diabetic Neuropathic Pain Drug Distributors List
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Diabetic Neuropathic Pain Drug Product Picture
    Figure 2. Global Diabetic Neuropathic Pain Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Diabetic Neuropathic Pain Drug Market Size 2017-2028 (US$ Million)
    Figure 4. Global Diabetic Neuropathic Pain Drug Sales 2017-2028 (K Pcs)
    Figure 5. United States Diabetic Neuropathic Pain Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Diabetic Neuropathic Pain Drug Market Size 2017-2028 (US$ Million)
    Figure 7. United States Diabetic Neuropathic Pain Drug Sales 2017-2028 (K Pcs)
    Figure 8. United States Diabetic Neuropathic Pain Drug Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Diabetic Neuropathic Pain Drug Market Share in Global, in Volume (K Pcs) 2017-2028
    Figure 10. Diabetic Neuropathic Pain Drug Report Years Considered
    Figure 11. Product Picture of AZD-5213
    Figure 12. Product Picture of Clonidine Hydrochloride
    Figure 13. Product Picture of Duloxetine Hydrochloride DR
    Figure 14. Product Picture of E-52862
    Figure 15. Product Picture of Filgrastim
    Figure 16. Product Picture of GERPOOI
    Figure 17. Product Picture of GRC-17536
    Figure 18. Product Picture of Others
    Figure 19. Global Diabetic Neuropathic Pain Drug Market Share by Type in 2022 & 2028
    Figure 20. Global Diabetic Neuropathic Pain Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 21. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type (2017-2028)
    Figure 22. Global Diabetic Neuropathic Pain Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 23. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 24. Global Diabetic Neuropathic Pain Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 25. United States Diabetic Neuropathic Pain Drug Market Share by Type in 2022 & 2028
    Figure 26. United States Diabetic Neuropathic Pain Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 27. United States Diabetic Neuropathic Pain Drug Sales Market Share in Value by Type (2017-2028)
    Figure 28. United States Diabetic Neuropathic Pain Drug Sales by Type (2017-2028) & (K Pcs)
    Figure 29. United States Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 30. United States Diabetic Neuropathic Pain Drug Price by Type (2017-2028) & (USD/Pcs)
    Figure 31. Product Picture of Clinic
    Figure 32. Product Picture of Hospital
    Figure 33. Product Picture of Others
    Figure 34. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2022 & 2028
    Figure 35. Global Diabetic Neuropathic Pain Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 36. Global Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2017-2028)
    Figure 37. Global Diabetic Neuropathic Pain Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 38. Global Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 39. Global Diabetic Neuropathic Pain Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 40. United States Diabetic Neuropathic Pain Drug Market Share by Application in 2022 & 2028
    Figure 41. United States Diabetic Neuropathic Pain Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 42. United States Diabetic Neuropathic Pain Drug Sales Market Share in Value by Application (2017-2028)
    Figure 43. United States Diabetic Neuropathic Pain Drug Sales by Application (2017-2028) & (K Pcs)
    Figure 44. United States Diabetic Neuropathic Pain Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 45. United States Diabetic Neuropathic Pain Drug Price by Application (2017-2028) & (USD/Pcs)
    Figure 46. North America Diabetic Neuropathic Pain Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 47. North America Diabetic Neuropathic Pain Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. U.S. Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Canada Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Europe Diabetic Neuropathic Pain Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 51. Europe Diabetic Neuropathic Pain Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 52. Germany Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. France Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. U.K. Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Italy Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Russia Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 58. Asia-Pacific Diabetic Neuropathic Pain Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 59. China Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Japan Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. South Korea Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. India Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Australia Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Taiwan Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Indonesia Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Thailand Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Malaysia Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Philippines Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Latin America Diabetic Neuropathic Pain Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 70. Latin America Diabetic Neuropathic Pain Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 71. Mexico Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Brazil Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Argentina Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Middle East & Africa Diabetic Neuropathic Pain Drug Sales in Volume Growth Rate 2017-2028 (K Pcs)
    Figure 75. Middle East & Africa Diabetic Neuropathic Pain Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 76. Turkey Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Saudi Arabia Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. U.A.E Diabetic Neuropathic Pain Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 79. Diabetic Neuropathic Pain Drug Value Chain
    Figure 80. Diabetic Neuropathic Pain Drug Production Process
    Figure 81. Channels of Distribution
    Figure 82. Distributors Profiles
    Figure 83. Bottom-up and Top-down Approaches for This Report
    Figure 84. Data Triangulation
    Figure 85. Key Executives Interviewed